Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in Patients With Schizophrenia

Phase II, Double Blind, Randomized, Placebo Controlled, Parallel Group, Trial to Explore Efficacy, Safety and Pharmacokinetics of CPL500036 (PDE10A Inhibitor) in Patients With an Acute Exacerbation of Schizophrenia

The purpose of this study is to determine the efficacy, safety, tolerability and pharmacokinetics (PK) properties of CPL500036 compound (PDE10a inhibitor) in patients with an acute exacerbation of schizophrenia after 28 days of administration..

Study Overview

• Status: Completed
• Conditions: Schizophrenia
• Intervention / Treatment: Drug: CPL500036 - low dose; Drug: CPL500036 - high dose; Drug: Placebo

Detailed Description

This is a double-blind, randomized, placebo controlled, parallel group, dose ranging study to explore the efficacy, safety, tolerability and PK of 2 different doses of CPL500036 (phosphodiesterase 10A [PDE10A] inhibitor) in patients with an acute exacerbation of schizophrenia. Approximately 165 patients will be randomized at a 1:1:1 ratio and will be dosed with 20 mg CPL500036, 40 mg CPL500036 or placebo once daily for 28 consecutive days (Day 1 to Day 28). Patients will remain in house for the duration of the Treatment Period. The study will comprise of a Screening Period (that will include a prior Medication Washout Period), a Treatment Period and a Follow-up Period. After discharge from the Clinical Unit, patients will return to the Clinical Unit for 2 once weekly Follow-up Visits. Approximately 30% of the patients (17 patients in each of the 3 treatment groups) will undergo extensive PK sampling during the Treatment Period, and the remaining 70% of the patients will only undergo sparse PK sampling.

• Study Type: Interventional
• Enrollment (Actual): 189
• Phase: Phase 2

Contacts and Locations

Study Locations

• Hungary
  • Budapest, Hungary, H-1083
    • Department of Psychiatry and Psychotheraapy of Semmelweis University
  • Budapest, Hungary, H-1085
    • Semmelweis University, Faculty of Medicine, Department of Psychiatry and Psychotherapy
  • Győr, Hungary, H-9024
    • Department of Psychiatry, Mental hygiene and Addictology of Petz Aladár County Teaching Hospital
  • Kalocsa, Hungary, H-6300
    • Bács-Kiskun County Teaching Hospital Kalocsa Holy Cross Hospital
  • Szekszárd, Hungary, H-7100
    • Psychiatry Department of Tolna County Balassa Janos Hospital
• Poland
  • Bialystok, Poland, 15-272
    • Uniwersytecki Szpital Kliniczny
  • Bolesławiec, Poland, 59-700
    • Wojewódzki Szpital dla Nerwowo i Psychicznie Chorych
  • Choroszcz, Poland, 16-070
    • Samodzielny Publiczny Psychiatryczny Zakład Opieki Zdrowotnej
  • Gmina Świecie, Poland, 86-100
    • Wojewódzki Szpital dla Psychicznie i Nerwowo Chorych
• Ukraine
  • Ivano-Frankivsk, Ukraine, 76014
    • Ivano-Frankivsk National Medical University, Department of Psychiatry, Narcology and Medical Psychology
  • Kyiv, Ukraine, 04080
    • Communal non-profit enterprise "Clinical Hospital "PSYCHIATRY"" of the executive body of the Kyiv City Council (Kyiv City State Administration), Center for Primary Psychotic Episode and Modern Treatment Methods.
  • Kyiv, Ukraine, 08631
    • Communal non-commercial enterprise of the Kyiv Regional Council "Regional Psychiatric-Narcological Medical Association", women's department No. 2, men's department No. 10.
  • Lviv, Ukraine, 79017
    • Communal non-commercial enterprise of the Lviv Regional Council "Lviv Regional Clinical Psychoneurological Dispensary",
  • Lviv, Ukraine, 79021
    • Communal non- commercial enterprise of Lviv Regional Council "Lviv Regional Clinical Psychiatric Hospital",
  • Ternopil, Ukraine, 46001
    • Ternopil National Medical University named after I.Y. Gorbachevskiy of the Ministry of Health of Ukraine, Department of Psychiatry, Narcology and Medical Psychology
  • Vinnytsia, Ukraine, 21018
    • Vinnytsia National Medical University named after M.I. Pirogov, Department of Psychiatry, Narcology and Psychotherapy with a course of postgraduate education

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. The patient has a primary diagnosis of schizophrenia confirmed by clinical interview [SCID-5-CT].
2. Male or female patient aged 18 to 65, inclusive, at Screening.
3. The patient's with exacerbation of psychotic symptoms
4. The patient has a score of 5 or higher in 3 or more items of the following PANSS items at Screening and Baseline
5. The patient has a PANSS Total Score of 80 or higher during Screening and on Baseline
6. The patient of childbearing potential willing to use acceptable forms of contraception.
7. The patient has a score in CGI-S scale of 4 or greater at Screening and on Baseline
8. The patient is able to and agrees to remain off prior antipsychotic medication and all excluded medications as outlined in the protocol for the duration of the Treatment Period.
9. The patient is able to sign informed consent after receiving information about the trial and has the ability and willingness to comply with the requirements and restrictions of the study protocol.

Exclusion Criteria:

1. The patient has a decrease in the PANSS Total Score at Baseline compared with the Total Score at Screening.
2. Patient who recently participated in another interventional clinical study with an Investigational Medicinal Product.
3. The patient has uncontrolled abnormality which may impact the ability of the patient to participate or potentially confound the study results.
4. The patient has a history of severe head injury, traumatic brain injury, myocardial infarction or stroke.
5. The patient has a moderate or severe substance use disorder for alcohol or other substances of abuse except nicotine or caffeine.
6. The patient is pregnant or lactating or intending to become pregnant or intending to donate ova.
7. The patient has a history of or known personality disorder or other psychiatric disorder that, in the opinion of the Investigator, would interfere with participation in the study.
8. The patient is considered by the Investigator to be at imminent risk of suicide or injury to self or others.
9. The patient has chronic movement disorder that may interfere with the interpretation of study results.
10. The patient has any existing or previous history of cancer or has newly diagnosed diabetes.
11. The patient has long QT syndrome or is under treatment with antiarrhythmic drugs.
12. The patient is considered to be treatment resistant. .
13. The patient has received electroconvulsive therapy.
14. The patient has any laboratory values outside the normal range that are considered by the Investigator to be clinically significant at Screening.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: CPL500036 low dose; Patients are to receive 20 mg of CPL500036 administered once dail for 28-days treatment period.	Drug: CPL500036 - low dose; CPL500036 is to be oral administered. Each patient is to take 2 capsules with active substance and 2 capsules of placebo daily.
Experimental: CPL500036 high dose; Patients are to receive 40 mg of CPL500036 administered once dail for 28-days treatment period.	Drug: CPL500036 - high dose; CPL500036 is to be oral administered. Each patient is to take 4 capsules with active substance daily.
Placebo Comparator: Placebo; Patients are to receive placebo administered once dail for 28-days treatment period.	Drug: Placebo; Placebo is to be oral administered. Each patient is to take 4 capsules of placebo daily.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline in PANSS positive subscale at Day 28.	The PANSS is a 30-item scale used to measure symptoms of schizophrenia. The scale has 7 positive symptom items, 7 negative symptom items, and 16 general psychopathology symptom items. Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient.Total score is 210 points. The higher PANSS total score, the more severe schizophrenia.	Day -1, Day 28

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline in PANSS positive subscale at Week 1, 2 and 3	The PANSS is a 30-item scale used to measure symptoms of schizophrenia. The scale has 7 positive symptom items, 7 negative symptom items, and 16 general psychopathology symptom items. Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient.Total score is 210 points. The higher PANSS total score, the more severe schizophrenia.	Day -1, Week 1, 2 and 3
Change from baseline in PANSS Total Score at Weeks 1, 2, 3, 4	The PANSS is a 30-item scale used to measure symptoms of schizophrenia. The scale has 7 positive symptom items, 7 negative symptom items, and 16 general psychopathology symptom items. Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient.Total score is 210 points. The higher PANSS total score, the more severe schizophrenia.	Day -1, Week 1, 2, 3 and 4
Change from Baseline in PANSS Subscales Using the Marder 5 factor Model at Weeks 1, 2, 3, and 4	The PANSS is a 30-item scale used to measure symptoms of schizophrenia.	Day -1, Week 1, 2, 3 and 4
Change from Baseline in PANSS Negative Subscales at Weeks 1, 2, 3 and 4	The PANSS is a 30-item scale used to measure symptoms of schizophrenia. The scale has 7 positive symptom items, 7 negative symptom items, and 16 general psychopathology symptom items. Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient.Total score is 210 points. The higher PANSS total score, the more severe schizophrenia.	Day -1, Week 1, 2, 3 and 4
Change from Baseline in PANSS general psychopathology Subscale at Weeks 1, 2, 3 and 4	The PANSS is a 30-item scale used to measure symptoms of schizophrenia. The scale has 7 positive symptom items, 7 negative symptom items, and 16 general psychopathology symptom items. Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient.Total score is 210 points. The higher PANSS total score, the more severe schizophrenia.	Day -1, Week 1, 2, 3 and 4
Percentage of Clinical Responders Based on the PANSS Total Score.	Clinical responder is defined as a ≥ 30% decrease from baseline.	Day -1, Week 1, 2, 3 and 4
Change from Baseline in Clinical Global Impression Severity (CGI-S) Score at Weeks 1, 2, 3, and 4	CGI-S scale is a physician-rated scale that is designed to rate the severity of the patient's illness at the time of assessment. It is a 7-point assessment where 1= normal (not at all ill) and 7 = among the most extremely ill patients.	Day -1, Week 1, 2, 3 and 4
Clinical Global Impression Scale Improvement (CGI-I) Score at Weeks 1, 2, 3, 4.	CGI-I is a 7 points scale that requires the clinician to assess how much the patient's illness has improved or worsened during treatment. It is a 7-point assessment where 1= Very much improved and 7 = Very much worse	Day -1, Week 1, 2, 3 and 4
Change from Baseline in Brief Assessment of Cognition in Schizophrenia (BACS) Score at Weeks 2 and 4.	BACS is specifically designed to measure treatment-related improvements in cognition. The BACS is a cognition assessment battery that assesses 6 domains of cognitive function found to be consistently impaired in schizophrenia: verbal memory, working memory, motor speed, attention, executive functions, and verbal fluency.	Day -1, Week 2 and 4
Number of abnormal clinically significant values in vital signs (heart rate, blood pressure, respiratory rate) results.		up to 6 weeks
Number of abnormal clinically significant findings in electrocardiogram results.	The following electrocardiogram parameters will be assess: PR interval, QRS interval, RR interval, QT interval and QTc interval.	up to 6 weeks
Number of abnormal clinically significant values in laboratory tests (hematologic, clinical chemistry, coagulation and urinalysis) results.		up to 6 weeks
Number of abnormal physical, neurological, ophthalmological and dermatological examination findings.		up to 6 weeks
Number and intensity of extrapyramidal side effects.	It will be assessed by using Extrapyramidal Symptom Rating Scale (ESRS). This scale is using to assess four types of drug-induced movement disorders (DIMD): Parkinsonism, akathisia, dystonia, and tardive dyskinesia.	up to 6 weeks
Number of adverse events.	All adverse events that occurence during study will be assessed.	up to 6 weeks
CPL500036 Cmax - Maximum observed concentration		up to 24 hours after administration on Day 7
CPL500036 Tmax - Time corresponding to occurrence of Cmax		up to 24 hours after administration on Day 7
CPL500036 AUC (0-24h) - Area under the curve from time zero to 24 hours		up to 24 hours after administration on Day 7
CPL500036 AUC T1/2 - Apparent terminal elimination half-life		up to 24 hours after administration on Day 7
CPL500036 CL/F (Apparent clearance) and Vz/F (apparent volume of distribution during terminal phase)		up to 24 hours after administration on Day 7
CPL500036 Cthrough - Concentration immediately prior to dosing		up to 24 hours after administration on Day 7

Collaborators and Investigators

• Sponsor: Celon Pharma SA
• Collaborators: National Center for Research and Development, Poland

Study record dates

Study Major Dates

• Study Start (Actual): May 19, 2021
• Primary Completion (Actual): June 5, 2024
• Study Completion (Actual): June 19, 2024

Study Registration Dates

• First Submitted: February 9, 2022
• First Submitted That Met QC Criteria: March 3, 2022
• First Posted (Actual): March 14, 2022

Study Record Updates

• Last Update Posted (Estimated): September 10, 2025
• Last Update Submitted That Met QC Criteria: September 3, 2025
• Last Verified: September 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Schizophrenia Spectrum and Other Psychotic Disorders; Mental Disorders; Schizophrenia; Substandard Drugs; Pharmaceutical Preparations; Counterfeit Drugs
• Other Study ID Numbers: 02PDE2019

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No